{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,24]],"date-time":"2026-09-24T22:37:26Z","timestamp":1790289446022,"version":"4.1.0"},"reference-count":101,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2018,10,1]],"date-time":"2018-10-01T00:00:00Z","timestamp":1538352000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2018,10]]},"DOI":"10.1016\/j.ejmech.2018.08.093","type":"journal-article","created":{"date-parts":[[2018,9,11]],"date-time":"2018-09-11T16:01:41Z","timestamp":1536681701000},"page":"559-592","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"special_numbering":"C","title":["DYRK1A kinase inhibition with emphasis on neurodegeneration: A comprehensive evolution story-cum-perspective"],"prefix":"10.1016","volume":"158","author":[{"given":"Ankita","family":"Pathak","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ankit","family":"Rohilla","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanya","family":"Gupta","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md Jawaid","family":"Akhtar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Md Rafi","family":"Haider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kalicharan","family":"Sharma","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kashif","family":"Haider","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9298-0154","authenticated-orcid":false,"given":"M. Shahar","family":"Yar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ejmech.2018.08.093_bib1","doi-asserted-by":"crossref","first-page":"857","DOI":"10.1021\/cn300094k","article-title":"Recent advances in the design, synthesis, and biological evaluation of selective DYRK1A inhibitors: a new avenue for a disease modifying treatment of Alzheimer's?","volume":"3","author":"Smith","year":"2012","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.ejmech.2018.08.093_bib2","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/ncomms1090","article-title":"Development of a novel selective inhibitor of the Down syndrome-related kinase Dyrk1A","volume":"1","author":"Ogawa","year":"2010","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2018.08.093_bib3","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.tcb.2006.12.002","article-title":"Molecular chaperones and protein kinase quality control","volume":"17","author":"Caplan","year":"2007","journal-title":"Trends Cell Biol."},{"key":"10.1016\/j.ejmech.2018.08.093_bib4","doi-asserted-by":"crossref","first-page":"pe22","DOI":"10.1126\/stke.3852007pe22","article-title":"Cdc37 regulation of the kinome: when to hold 'em and when to fold 'em","volume":"2007","author":"Karnitz","year":"2007","journal-title":"Sci. STKE"},{"key":"10.1016\/j.ejmech.2018.08.093_bib5","doi-asserted-by":"crossref","first-page":"246","DOI":"10.1111\/j.1742-4658.2010.07956.x","article-title":"Activation, regulation, and inhibition of DYRK1A","volume":"278","author":"Becker","year":"2011","journal-title":"FEBS J."},{"key":"10.1016\/j.ejmech.2018.08.093_bib6","doi-asserted-by":"crossref","first-page":"1305","DOI":"10.1093\/hmg\/5.9.1305","article-title":"A\u00a0human homologue of Drosophila minibrain (MNB) is expressed in the neuronal regions affected in Down syndrome and maps to the critical region","volume":"5","author":"Guimera","year":"1996","journal-title":"Hum. Mol. Genet."},{"key":"10.1016\/j.ejmech.2018.08.093_bib7","doi-asserted-by":"crossref","first-page":"331","DOI":"10.1006\/geno.1996.0636","article-title":"Isolation of human and murine homologues of the Drosophila minibrain gene: human homologue maps to 21q22.2 in the Down syndrome \"critical region\"","volume":"38","author":"Song","year":"1996","journal-title":"Genomics"},{"key":"10.1016\/j.ejmech.2018.08.093_bib8","doi-asserted-by":"crossref","first-page":"3235","DOI":"10.1007\/s00018-009-0123-2","article-title":"Function and regulation of Dyrk1A: towards understanding Down syndrome","volume":"66","author":"Park","year":"2009","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.ejmech.2018.08.093_bib9","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1016\/j.bmcl.2017.03.037","article-title":"Developing DYRK inhibitors derived from the meridianins as a means of increasing levels of NFAT in the nucleus","volume":"27","author":"Shaw","year":"2017","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2018.08.093_bib10","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1111\/j.1471-4159.2007.05075.x","article-title":"Dual-specificity tyrosine(Y)-phosphorylation regulated kinase 1A-mediated phosphorylation of amyloid precursor protein: evidence for a functional link between Down syndrome and Alzheimer's disease","volume":"104","author":"Ryoo","year":"2008","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.ejmech.2018.08.093_bib11","doi-asserted-by":"crossref","first-page":"12728","DOI":"10.1038\/srep12728","article-title":"Identification of a DYRK1A inhibitor that induces degradation of the target kinase using Co-chaperone CDC37 fused with luciferase nanoKAZ","volume":"5","author":"Sonamoto","year":"2015","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2018.08.093_bib12","doi-asserted-by":"crossref","first-page":"11391","DOI":"10.1038\/ncomms11391","article-title":"Selective inhibition of the kinase DYRK1A by targeting its folding process","volume":"7","author":"Kii","year":"2016","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2018.08.093_bib13","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1016\/j.phrs.2003.12.028","article-title":"The role of beta amyloid in Alzheimer's disease: still a cause of everything or the only one who got caught?","volume":"50","author":"Verdile","year":"2004","journal-title":"Pharmacol. Res."},{"key":"10.1016\/j.ejmech.2018.08.093_bib14","doi-asserted-by":"crossref","first-page":"609","DOI":"10.1007\/s11064-006-9131-x","article-title":"The role of presenilin and its interacting proteins in the biogenesis of Alzheimer's beta amyloid","volume":"32","author":"Verdile","year":"2007","journal-title":"Neurochem. Res."},{"key":"10.1016\/j.ejmech.2018.08.093_bib15","doi-asserted-by":"crossref","first-page":"440","DOI":"10.1111\/jnc.13018","article-title":"A\u00a0novel DYRK1A (dual specificity tyrosine phosphorylation-regulated kinase 1A) inhibitor for the treatment of Alzheimer's disease: effect on Tau and amyloid pathologies in\u00a0vitro","volume":"133","author":"Coutadeur","year":"2015","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.ejmech.2018.08.093_bib16","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1111\/acel.12648","article-title":"Dyrk1 inhibition improves Alzheimer's disease-like pathology","volume":"16","author":"Branca","year":"2017","journal-title":"Aging Cell"},{"key":"10.1016\/j.ejmech.2018.08.093_bib17","doi-asserted-by":"crossref","first-page":"311","DOI":"10.3233\/JAD-2010-1221","article-title":"Alzheimer's disease and the amyloid-beta peptide","volume":"19","author":"Murphy","year":"2010","journal-title":"J.\u00a0Alzheimers Dis."},{"key":"10.1016\/j.ejmech.2018.08.093_bib18","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1038\/35015085","article-title":"Photoactivated gamma-secretase inhibitors directed to the active site covalently label presenilin 1","volume":"405","author":"Li","year":"2000","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2018.08.093_bib19","doi-asserted-by":"crossref","first-page":"8698","DOI":"10.1021\/bi0005456","article-title":"L-685,458, an aspartyl protease transition state mimic, is a potent inhibitor of amyloid beta-protein precursor gamma-secretase activity","volume":"39","author":"Shearman","year":"2000","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2018.08.093_bib20","doi-asserted-by":"crossref","first-page":"39062","DOI":"10.1074\/jbc.C200469200","article-title":"PEN-2 is an integral component of the gamma-secretase complex required for coordinated expression of presenilin and nicastrin","volume":"277","author":"Steiner","year":"2002","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2018.08.093_bib21","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/S1534-5807(02)00189-2","article-title":"aph-1 and pen-2 are required for Notch pathway signaling, gamma-secretase cleavage of betaAPP, and presenilin protein accumulation","volume":"3","author":"Francis","year":"2002","journal-title":"Dev. Cell"},{"key":"10.1016\/j.ejmech.2018.08.093_bib22","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1038\/19077","article-title":"Two transmembrane aspartates in presenilin-1 required for presenilinendoproteolysis and gamma-secretase activity","volume":"398","author":"Wolfe","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.ejmech.2018.08.093_bib23","doi-asserted-by":"crossref","first-page":"6138","DOI":"10.1073\/pnas.110126897","article-title":"Presenilin 1 is linked with gamma-secretase activity in the detergent solubilized state","volume":"97","author":"Li","year":"2000","journal-title":"ProcNatlAcadSci U S A"},{"key":"10.1016\/j.ejmech.2018.08.093_bib24","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1038\/35017062","article-title":"Transition-state analogue inhibitors of gamma-secretase bind directly to presenilin-1","volume":"2","author":"Esler","year":"2000","journal-title":"Nat. Cell Biol."},{"key":"10.1016\/j.ejmech.2018.08.093_bib25","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0169-328X(00)00230-8","article-title":"Positive-negative epitope-tagging of beta amyloid precursor protein to identify inhibitors of A beta processing","volume":"84","author":"Seiffert","year":"2000","journal-title":"Brain Res Mol. Brain Res."},{"key":"10.1016\/j.ejmech.2018.08.093_bib26","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1111\/j.1471-4159.2010.06769.x","article-title":"Dyrk1A-mediated phosphorylation of Presenilin 1: a functional link between Down syndrome and Alzheimer's disease","volume":"115","author":"Ryu","year":"2010","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.ejmech.2018.08.093_bib27","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1038\/s41598-017-00682-y","article-title":"Dyrk1A overexpression leads to increase of 3R-tau expression and cognitive deficits in Ts65Dn Down syndrome mice","volume":"7","author":"Yin","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ejmech.2018.08.093_bib28","doi-asserted-by":"crossref","first-page":"15153","DOI":"10.1074\/jbc.M309305200","article-title":"Signal peptide peptidase forms a homodimer that is labeled by an active site-directed gamma-secretase inhibitor","volume":"279","author":"Nyborg","year":"2004","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2018.08.093_bib29","doi-asserted-by":"crossref","first-page":"1671","DOI":"10.1096\/fj.06-5762com","article-title":"Intramembraneproteolytic cleavage by human signal peptide peptidase like 3 and malaria signal peptide peptidase","volume":"20","author":"Nyborg","year":"2006","journal-title":"Faseb. J."},{"key":"10.1016\/j.ejmech.2018.08.093_bib30","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S1097-2765(02)00655-X","article-title":"Requirements for signal peptide peptidase-catalyzed intramembrane proteolysis","volume":"10","author":"Lemberg","year":"2002","journal-title":"Mol. Cell"},{"key":"10.1016\/j.ejmech.2018.08.093_bib31","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1021\/acschemneuro.5b00316","article-title":"Amyloid plaque-associated oxidative degradation of uniformly radiolabeled arachidonic acid","volume":"7","author":"Furman","year":"2016","journal-title":"ACS Chem. Neurosci."},{"key":"10.1016\/j.ejmech.2018.08.093_bib32","first-page":"35","article-title":"Dyrk1A positively stimulates ASK1-JNK signaling pathway during apoptotic cell death","volume":"20","author":"Choi","year":"2011","journal-title":"ExpNeurobiol"},{"key":"10.1016\/j.ejmech.2018.08.093_bib33","doi-asserted-by":"crossref","first-page":"58","DOI":"10.2478\/s11658-012-0039-y","article-title":"Pharmacological inhibition of GSK3 attenuates DNA damage-induced apoptosis via reduction of p53 mitochondrial translocation and Baxoligomerization in neuroblastoma SH-SY5Y cells","volume":"18","author":"Ngok-Ngam","year":"2013","journal-title":"Cell. Mol. Biol. Lett."},{"key":"10.1016\/j.ejmech.2018.08.093_bib34","doi-asserted-by":"crossref","first-page":"11553","DOI":"10.1074\/jbc.275.16.11553","article-title":"E2F1 mediates death of B-amyloid-treated cortical neurons in a manner independent of p53 and dependent on Bax and caspase 3","volume":"275","author":"Giovanni","year":"2000","journal-title":"J.\u00a0Biol. Chem."},{"key":"10.1016\/j.ejmech.2018.08.093_bib35","doi-asserted-by":"crossref","first-page":"2170","DOI":"10.1016\/j.euroneuro.2015.03.018","article-title":"Leucettine L41, a DYRK1A-preferential DYRKs\/CLKs inhibitor, prevents memory impairments and neurotoxicity induced by oligomeric Abeta25-35 peptide administration in mice","volume":"25","author":"Naert","year":"2015","journal-title":"Eur. Neuropsychopharmacol"},{"key":"10.1016\/j.ejmech.2018.08.093_bib36","series-title":"Current and Future Approaches to Therapy of Alzheimer's Disease","first-page":"565","author":"Kan","year":"1992"},{"key":"10.1016\/j.ejmech.2018.08.093_bib37","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1016\/j.bmc.2013.03.058","article-title":"Microwave assisted synthesis, cholinesterase enzymes inhibitory activities and molecular docking studies of new pyridopyrimidine derivatives","volume":"21","author":"Basiri","year":"2013","journal-title":"Bioorg. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.08.093_bib38","doi-asserted-by":"crossref","first-page":"6324","DOI":"10.1111\/j.1742-4658.2009.07346.x","article-title":"Harmine specifically inhibits protein kinase DYRK1A and interferes with neurite formation","volume":"276","author":"Gockler","year":"2009","journal-title":"FEBS J."},{"key":"10.1016\/j.ejmech.2018.08.093_bib39","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1016\/j.abb.2010.12.024","article-title":"Harmine is an ATP-competitive inhibitor for dual-specificity tyrosine phosphorylation-regulated kinase 1A (Dyrk1A)","volume":"507","author":"Adayev","year":"2011","journal-title":"Arch. Biochem. Biophys."},{"key":"10.1016\/j.ejmech.2018.08.093_bib40","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0019264","article-title":"beta-carboline compounds, including harmine, inhibit DYRK1A and tau phosphorylation at multiple Alzheimer's disease-related sites","volume":"6","author":"Frost","year":"2011","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2018.08.093_bib41","doi-asserted-by":"crossref","first-page":"4854","DOI":"10.1016\/j.bmcl.2014.08.054","article-title":"Computational & experimental evaluation of the structure\/activity relationship of beta-carbolines as DYRK1A inhibitors","volume":"24","author":"Drung","year":"2014","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2018.08.093_bib42","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0132453","article-title":"Selectivity profiling and biological activity of novel beta-carbolines as potent and selective DYRK1 kinase inhibitors","volume":"10","author":"Ruben","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.ejmech.2018.08.093_bib43","series-title":"Fakult\u00e4tf\u00fcrMathematik, Informatik und Naturwissenschaften der RWTH","article-title":"Novel harmine analogs and the effect on dual specificity kinase activity of DYRK1A","author":"Ruben","year":"2015"},{"key":"10.1016\/j.ejmech.2018.08.093_bib44","doi-asserted-by":"crossref","first-page":"3131","DOI":"10.1021\/jm501994d","article-title":"10-iodo-11H-indolo[3,2-c]quinoline-6-carboxylic acids are selective inhibitors of DYRK1A","volume":"58","author":"Falke","year":"2015","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.08.093_bib45","doi-asserted-by":"crossref","first-page":"6489","DOI":"10.1021\/jm300542e","article-title":"Novel trisubstitutedharmine derivatives with original in\u00a0vitro anticancer activity","volume":"55","author":"Frederick","year":"2012","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.08.093_bib46","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1042\/bj20021535","article-title":"The specificities of protein kinase inhibitors: an update","volume":"371","author":"Bain","year":"2003","journal-title":"Biochem. J."},{"key":"10.1016\/j.ejmech.2018.08.093_bib47","doi-asserted-by":"crossref","first-page":"12011","DOI":"10.1021\/bi060632j","article-title":"Kinetic properties of a MNB\/DYRK1A mutant suitable for the elucidation of biochemical pathways","volume":"45","author":"Adayev","year":"2006","journal-title":"Biochemistry"},{"key":"10.1016\/j.ejmech.2018.08.093_bib48","doi-asserted-by":"crossref","first-page":"278","DOI":"10.1002\/mnfr.201300325","article-title":"Epigallocatechin-3-gallate, a DYRK1A inhibitor, rescues cognitive deficits in Down syndrome mouse models and in humans","volume":"58","author":"De la Torre","year":"2014","journal-title":"Mol. Nutr. Food Res."},{"key":"10.1016\/j.ejmech.2018.08.093_bib49","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1007\/s00018-011-0758-7","article-title":"Structural features underlying the selectivity of the kinase inhibitors NBC and dNBC: role of a nitro group that discriminates between CK2 and DYRK1A","volume":"69","author":"Sarno","year":"2012","journal-title":"Cell. Mol. Life Sci."},{"key":"10.1016\/j.ejmech.2018.08.093_bib50","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1038\/ncomms1090","article-title":"Development of a novel selective inhibitor of the Down syndrome-related kinase Dyrk1A","volume":"1","author":"Ogawa","year":"2010","journal-title":"Nat. Commun."},{"key":"10.1016\/j.ejmech.2018.08.093_bib51","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1042\/BJ20090069","article-title":"Quinalizarin as a potent, selective and cell-permeable inhibitor of protein kinase CK2","volume":"421","author":"Cozza","year":"2009","journal-title":"Biochem. J."},{"key":"10.1016\/j.ejmech.2018.08.093_bib52","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1055\/s-0029-1186226","article-title":"Two new peltogynoids from Acacia niloticaDelile with kinase inhibitory activity","volume":"76","author":"Ahmadu","year":"2010","journal-title":"Planta Med."},{"key":"10.1016\/j.ejmech.2018.08.093_bib53","doi-asserted-by":"crossref","first-page":"371","DOI":"10.3109\/14756366.2014.940932","article-title":"Synthesis of new isoxazoline derivatives from harmine and evaluation of their anti-Alzheimer, anti-cancer and anti-inflammatory activities","volume":"30","author":"Filali","year":"2015","journal-title":"J.\u00a0Enzym. Inhib. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.08.093_bib54","series-title":"Generation of Potent and Selective Kinase Inhibitors by Combinatorial Biosynthesis of Glycosylated Indolocarbazoles","first-page":"4118","author":"Sanchez","year":"2009"},{"key":"10.1016\/j.ejmech.2018.08.093_bib55","doi-asserted-by":"crossref","first-page":"9312","DOI":"10.1021\/jm301034u","article-title":"Selectivity, cocrystal structures, and neuroprotective properties of leucettines, a family of protein kinase inhibitors derived from the marine sponge alkaloid leucettamine B","volume":"55","author":"Tahtouh","year":"2012","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.08.093_bib56","doi-asserted-by":"crossref","first-page":"4172","DOI":"10.1021\/jm200274d","article-title":"Leucettines, a class of potent inhibitors of cdc2-like kinases and dual specificity, tyrosine phosphorylation regulated kinases derived from the marine sponge leucettamine B: modulation of alternative pre-RNA splicing","volume":"54","author":"Debdab","year":"2011","journal-title":"J.\u00a0Med. Chem."},{"issue":"6","key":"10.1016\/j.ejmech.2018.08.093_bib57","first-page":"025","article-title":"Exploring the synthesis of new 1-(4-substitutedphenylamino) imidazo[1,5-a]indol-3-one derivatives as cyclized analogs of leucettines","volume":"4","author":"Burgy","year":"2014","journal-title":"J.\u00a0Appl. Pharmaceut. Sci."},{"key":"10.1016\/j.ejmech.2018.08.093_bib58","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.ejmech.2013.01.035","article-title":"Chemical synthesis and biological validation of immobilized protein kinase inhibitory Leucettines","volume":"62","author":"Burgy","year":"2013","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.08.093_bib59","doi-asserted-by":"crossref","first-page":"7289","DOI":"10.1021\/jm400719y","article-title":"Synthesis, resolution, and biological evaluation of atropisomeric (aR)- and (aS)-16-methyllamellarins N: unique effects of the axial chirality on the selectivity of protein kinases inhibition","volume":"56","author":"Yoshida","year":"2013","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.08.093_bib60","doi-asserted-by":"crossref","first-page":"379","DOI":"10.1016\/j.ejmech.2012.01.040","article-title":"Synthesis of chromeno[3,4-b]indoles as Lamellarin D analogues: a novel DYRK1A inhibitor class","volume":"49","author":"Neagoie","year":"2012","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.08.093_bib61","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1021\/ml300207a","article-title":"Novel inverse binding mode of indirubin derivatives yields improved selectivity for DYRK kinases","volume":"4","author":"Myrianthopoulos","year":"2013","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2018.08.093_bib62","doi-asserted-by":"crossref","first-page":"3018","DOI":"10.3390\/molecules18033018","article-title":"Natural aristolactams and aporphine alkaloids as inhibitors of CDK1\/cyclin B and DYRK1A","volume":"18","author":"Marti","year":"2013","journal-title":"Molecules"},{"key":"10.1016\/j.ejmech.2018.08.093_bib63","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1016\/j.tet.2013.11.057","article-title":"Didemnaketals D and E, bioactive terpenoids from a Red Sea ascidian Didemnum species","volume":"70","author":"Mohamed","year":"2014","journal-title":"Tetrahedron"},{"key":"10.1016\/j.ejmech.2018.08.093_bib64","doi-asserted-by":"crossref","first-page":"2492","DOI":"10.1021\/jm200039m","article-title":"A\u00a0one-pot synthesis and biological activity of ageladine A and analogues","volume":"54","author":"Shengule","year":"2011","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.08.093_bib65","doi-asserted-by":"crossref","first-page":"4474","DOI":"10.1021\/jm200464w","article-title":"Synthesis, protein kinase inhibitory potencies, and in\u00a0vitro antiproliferative activities of meridianin derivatives","volume":"54","author":"Giraud","year":"2011","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.08.093_bib66","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1021\/jm700940h","article-title":"Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2\/cyclin A\/meriolin complex","volume":"51","author":"Echalier","year":"2008","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.08.093_bib67","doi-asserted-by":"crossref","first-page":"2948","DOI":"10.1016\/j.bmcl.2015.05.034","article-title":"Meridianin derivatives as potent Dyrk1A inhibitors and neuroprotective agents","volume":"25","author":"Yadav","year":"2015","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2018.08.093_bib68","doi-asserted-by":"crossref","first-page":"2617","DOI":"10.1016\/j.bmcl.2017.03.037","article-title":"Developing DYRK inhibitors derived from the meridianins as a means of increasing levels of NFAT in the nucleus","volume":"27","author":"Shaw","year":"2017","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2018.08.093_bib69","doi-asserted-by":"crossref","first-page":"6700","DOI":"10.1016\/j.bmcl.2009.09.121","article-title":"Evaluation of substituted 6-arylquinazolin-4-amines as potent and selective inhibitors of cdc2-like kinases (Clk)","volume":"19","author":"Mott","year":"2009","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2018.08.093_bib70","doi-asserted-by":"crossref","first-page":"3152","DOI":"10.1016\/j.bmcl.2011.02.114","article-title":"Potent and selective small molecule inhibitors of specific isoforms of Cdc2-like kinases (Clk) and dual specificity tyrosine-phosphorylation-regulated kinases (Dyrk)","volume":"21","author":"Rosenthal","year":"2011","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2018.08.093_bib71","series-title":"Dyrk1a Inhibitors and Uses Thereof","author":"Leblond","year":"2013"},{"key":"10.1016\/j.ejmech.2018.08.093_bib72","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ejmech.2014.10.084","article-title":"Synthetic approaches, functionalization and therapeutic potential of quinazoline and quinazolinone skeletons: the advances continue","volume":"90","author":"Khan","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.08.093_bib73","doi-asserted-by":"crossref","first-page":"2324","DOI":"10.1016\/j.bmcl.2009.02.062","article-title":"QSAR analysis of pyrazolidine-3,5-diones derivatives as Dyrk1A inhibitors","volume":"19","author":"Koo","year":"2009","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2018.08.093_bib74","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1016\/j.ejmech.2012.11.030","article-title":"Synthesis and biological evaluation of N-aryl-7-methoxybenzo[b]furo[3,2-d]pyrimidin-4-amines and their N-arylbenzo[b]thieno[3,2-d]pyrimidin-4-amine analogues as dual inhibitors of CLK1 and DYRK1A kinases","volume":"59","author":"Loidreau","year":"2013","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.08.093_bib75","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1002\/ijc.27917","article-title":"Ovarian cancer cells, not normal cells, are damaged by Mirk\/Dyrk1B kinase inhibition","volume":"132","author":"Hu","year":"2013","journal-title":"Int. J. Canc."},{"key":"10.1016\/j.ejmech.2018.08.093_bib76","doi-asserted-by":"crossref","first-page":"6610","DOI":"10.1016\/j.bmcl.2013.10.055","article-title":"Pyrido[2,3-d]pyrimidines: discovery and preliminary SAR of a novel series of DYRK1B and DYRK1A inhibitors","volume":"23","author":"Anderson","year":"2013","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2018.08.093_bib77","doi-asserted-by":"crossref","first-page":"3654","DOI":"10.1016\/j.bmcl.2013.02.096","article-title":"Small-molecule pyrimidine inhibitors of the cdc2-like (Clk) and dual specificity tyrosine phosphorylation-regulated (Dyrk) kinases: development of chemical probe ML315","volume":"23","author":"Coombs","year":"2013","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2018.08.093_bib78","doi-asserted-by":"crossref","first-page":"6784","DOI":"10.1016\/j.bmcl.2013.10.019","article-title":"Synthesis of novel 7-substituted pyrido[2',3':4,5]furo[3,2-d]pyrimidin-4-amines and their N-aryl analogues and evaluation of their inhibitory activity against Ser\/Thr kinases","volume":"23","author":"Deau","year":"2013","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2018.08.093_bib79","doi-asserted-by":"crossref","first-page":"291","DOI":"10.1016\/j.ejmech.2016.01.011","article-title":"5-Substituted 3-isopropyl-7-[4-(2-pyridyl)benzyl]amino-1(2)H-pyrazolo[4,3-d]pyrimidines with anti-proliferative activity as potent and selective inhibitors of cyclin-dependent kinases","volume":"110","author":"Vymetalova","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.08.093_bib80","doi-asserted-by":"crossref","first-page":"3402","DOI":"10.1016\/j.bmcl.2005.05.021","article-title":"(1H-imidazo[4,5-c]pyridin-2-yl)-1,2,5-oxadiazol-3-ylamine derivatives: a novel class of potent MSK-1-inhibitors","volume":"15","author":"Bamford","year":"2005","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2018.08.093_bib81","doi-asserted-by":"crossref","first-page":"4566","DOI":"10.1016\/j.bmcl.2009.06.099","article-title":"Synthesis and biological evaluation of 3,6-diamino-1H-pyrazolo[3,4-b]pyridine derivatives as protein kinase inhibitors","volume":"19","author":"Chioua","year":"2009","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2018.08.093_bib82","doi-asserted-by":"crossref","first-page":"5416","DOI":"10.1016\/j.ejmech.2011.08.048","article-title":"Synthesis and biological evaluation of new 3-(6-hydroxyindol-2-yl)-5-(Phenyl) pyridine or pyrazine V-Shaped molecules as kinase inhibitors and cytotoxic agents","volume":"46","author":"Kassis","year":"2011","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.08.093_bib83","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ejmech.2012.08.033","article-title":"Synthesis and biological evaluation of selective and potent cyclin-dependent kinase inhibitors","volume":"56","author":"N'Gompaza-Diarra","year":"2012","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.08.093_bib84","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1016\/j.bmcl.2012.10.141","article-title":"Potent inhibitors of CDK5 derived from roscovitine: synthesis, biological evaluation and molecular modelling","volume":"23","author":"Demange","year":"2013","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2018.08.093_bib85","doi-asserted-by":"crossref","first-page":"9569","DOI":"10.1021\/jm401049v","article-title":"Development of DANDYs, new 3,5-diaryl-7-azaindoles demonstrating potent DYRK1A kinase inhibitory activity","volume":"56","author":"Gourdain","year":"2013","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.08.093_bib86","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.bmcl.2007.12.037","article-title":"Pyrazinoindolone inhibitors of MAPKAP-K2","volume":"18","author":"Goldberg","year":"2008","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2018.08.093_bib87","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1002\/(SICI)1098-1128(200001)20:1<28::AID-MED2>3.0.CO;2-2","article-title":"ATP site-directed competitive and irreversible inhibitors of protein kinases","volume":"20","author":"Garcia-Echeverria","year":"2000","journal-title":"Med. Res. Rev."},{"key":"10.1016\/j.ejmech.2018.08.093_bib88","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1016\/j.bmcl.2013.02.027","article-title":"Design, synthesis, and molecular modelling of pyridazinone and phthalazinone derivatives as protein kinases inhibitors","volume":"23","author":"Elagawany","year":"2013","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2018.08.093_bib89","doi-asserted-by":"crossref","first-page":"225","DOI":"10.1016\/j.ejmech.2012.09.001","article-title":"Synthesis and biological evaluation of new 5-benzylated 4-oxo-3,4-dihydro-5H-pyridazino[4,5-b]indoles as PI3Kalpha inhibitors","volume":"57","author":"Bruel","year":"2012","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.08.093_bib90","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1042\/BJ20130461","article-title":"A\u00a0novel DYRK1B inhibitor AZ191 demonstrates that DYRK1B acts independently of GSK3beta to phosphorylate cyclin D1 at Thr(286), not Thr(288)","volume":"457","author":"Ashford","year":"2014","journal-title":"Biochem. J."},{"key":"10.1016\/j.ejmech.2018.08.093_bib91","doi-asserted-by":"crossref","first-page":"5818","DOI":"10.1021\/om400359m","article-title":"Synthesis of oxindole-based bioorganometallic kinase inhibitors incorporating one or more ferrocene groups","volume":"32","author":"Amin","year":"2013","journal-title":"Organometallics"},{"key":"10.1016\/j.ejmech.2018.08.093_bib92","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1039\/c1md00141h","article-title":"Synthesis and biological evaluation of 2,3-bis(het)aryl-4-azaindole derivatives as protein kinase inhibitors","volume":"2","author":"Pin","year":"2011","journal-title":"MedChemComm"},{"key":"10.1016\/j.ejmech.2018.08.093_bib93","doi-asserted-by":"crossref","first-page":"5672","DOI":"10.1016\/j.bmcl.2008.08.072","article-title":"Identification of novel protein kinase CK1 delta (CK1delta) inhibitors through structure-based virtual screening","volume":"18","author":"Cozza","year":"2008","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2018.08.093_bib94","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1016\/j.bbapap.2013.01.018","article-title":"Exploiting the repertoire of CK2 inhibitors to target DYRK and PIM kinases","volume":"1834","author":"Cozza","year":"2013","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.ejmech.2018.08.093_bib95","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.ejmech.2014.11.051","article-title":"Pyrazoloquinazolines: synthetic strategies and bioactivities","volume":"97","author":"Garg","year":"2015","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2018.08.093_bib96","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1021\/ml500059y","article-title":"Hydroxybenzothiophene ketones are efficient pre-mRNA splicing modulators due to dual inhibition of Dyrk1A and Clk1\/4","volume":"5","author":"Schmitt","year":"2014","journal-title":"ACS Med. Chem. Lett."},{"key":"10.1016\/j.ejmech.2018.08.093_bib97","doi-asserted-by":"crossref","first-page":"168","DOI":"10.1016\/j.bmcl.2011.11.043","article-title":"Discovery of potent small molecule inhibitors of DYRK1A by structure-based virtual screening and bioassay","volume":"22","author":"Wang","year":"2012","journal-title":"Bioorg. Med. Chem. Lett"},{"key":"10.1016\/j.ejmech.2018.08.093_bib98","doi-asserted-by":"crossref","first-page":"5664","DOI":"10.1021\/jm050761i","article-title":"Design and biological evaluation of novel tubulin inhibitors as antimitotic agents using a pharmacophore binding model with tubulin","volume":"49","author":"Kim","year":"2006","journal-title":"J.\u00a0Med. Chem."},{"key":"10.1016\/j.ejmech.2018.08.093_bib99","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1038\/nrd2111","article-title":"Untangling tau hyperphosphorylation in drug design for neurodegenerative diseases","volume":"6","author":"Mazanetz","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.ejmech.2018.08.093_bib100","doi-asserted-by":"crossref","first-page":"1108","DOI":"10.1002\/prot.25056","article-title":"Insights into mechanism of pyrido[2,3-d]pyrimidines as DYRK1A inhibitors based on molecular dynamic simulations","volume":"84","author":"Li","year":"2016","journal-title":"Proteins"},{"key":"10.1016\/j.ejmech.2018.08.093_bib101","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1016\/j.jmgm.2017.01.014","article-title":"Multi-step virtual screening to develop selective DYRK1A inhibitors","volume":"72","author":"Koyama","year":"2017","journal-title":"J.\u00a0Mol. Graph. Model."}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523418307657?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523418307657?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,1]],"date-time":"2025-10-01T13:48:09Z","timestamp":1759326489000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523418307657"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,10]]},"references-count":101,"alternative-id":["S0223523418307657"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2018.08.093","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2018,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"DYRK1A kinase inhibition with emphasis on neurodegeneration: A comprehensive evolution story-cum-perspective","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2018.08.093","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2018 Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}